RSV Vaccine Biz Secures $100M For Series B Funding Round

By Jade Martinez-Pogue · September 23, 2024, 3:07 PM EDT

Biopharmaceutical company Vicebio Ltd. on Monday announced that it secured its Series B funding round after securing $100 million led by science-focused investment firm TCGX....

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Recent Articles By Jade

October 29, 2024
Warren Pushes FTC Chair To Probe Oncology Acquisitions
October 08, 2024
Renovus Capital Clinches 4th PE Fund With $875M In Tow
October 07, 2024
Kirkland-Led Shore Capital Lands Almost $2B Across 3 Funds
October 01, 2024
Latham Helps TJC Clinch 2nd Continuation Fund At $2.1B
September 25, 2024
Cancer Detection Biz To Go Public Via $694M SPAC Merger
September 20, 2024
Cardinal Health Pays $1.12B For Integrated Oncology Network
September 18, 2024
Organon To Buy Psoriasis Treatment Biz For Up To $1.2B
September 09, 2024
MBX Biosciences Seeks Up To $136M In Upcoming IPO
September 03, 2024
Aspire Biopharma Inks SPAC Deal At $316M Valuation
September 03, 2024
Semnur Pharmaceuticals To Go Public Via $2.5B SPAC Merger